CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Addex Therapeutics Ltd. (ADXN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Addex Therapeutics Ltd. (ADXN)

Pharmaceutical Preparations · market cap $7M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-03 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Addex Therapeutics Ltd. (ADXN) is a micro-cap pharmaceutical company with a market cap of approximately $8M, 2 employees, and three Phase 2 assets: ADX10059 (gastroesophageal reflux), ADX48621 (Parkinson's disease), and Dipraglurant (blepharospasm). Financial details including cash, runway, and dilution history are undisclosed, though dilution risk is flagged as elevated at 27% and no upcoming catalysts are on the calendar.
The catalyst path
  • 2026-12-03 (est.)Earningsimp 5/10
Pipeline
AssetPhaseIndication
ADX10059Phase 2Gastroesophageal Reflux
ADX48621Phase 2Parkinson's Disease
DipraglurantPhase 2Blepharospasm
Price & technical context
3-month
-35.8%
6-month
-46.4%
12-month
-57.4%
52-wk range
$2.65–$8.99
vs 50-day MA
+14.7%
vs 200-day MA
-33.9%
Realized vol
105.8%
Max drawdown
-76.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ADXN (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.